AD Hydrogen Sulfide and Gasotransmitter Therapy Companies
Overview
flowchart TD
companies_ad_hydrogen_sulfide_["AD Hydrogen Sulfide and Gasotransmitter Therapy"]
style companies_ad_hydrogen_sulfide_ fill:#4fc3f7,stroke:#333,color:#000
companies_ad_hydroge_0["Key Mechanisms"]
companies_ad_hydrogen_sulfide_ -->|"includes"| companies_ad_hydroge_0
style companies_ad_hydroge_0 fill:#81c784,stroke:#333,color:#000
companies_ad_hydroge_1["Hydrogen Sulfide H2S Donors"]
companies_ad_hydrogen_sulfide_ -->|"includes"| companies_ad_hydroge_1
style companies_ad_hydroge_1 fill:#ef5350,stroke:#333,color:#000
companies_ad_hydroge_2["CO-Releasing Molecules CORMs"]
companies_ad_hydrogen_sulfide_ -->|"includes"| companies_ad_hydroge_2
style companies_ad_hydroge_2 fill:#ffd54f,stroke:#333,color:#000
companies_ad_hydroge_3["NO Pathway Modulators"]
companies_ad_hydrogen_sulfide_ -->|"includes"| companies_ad_hydroge_3
style companies_ad_hydroge_3 fill:#ce93d8,stroke:#333,color:#000
companies_ad_hydroge_4["Companies"]
companies_ad_hydrogen_sulfide_ -->|"includes"| companies_ad_hydroge_4
style companies_ad_hydroge_4 fill:#4fc3f7,stroke:#333,color:#000
companies_ad_hydroge_5["E-Discovery Therapeutics"]
companies_ad_hydrogen_sulfide_ -->|"includes"| companies_ad_hydroge_5
style companies_ad_hydroge_5 fill:#81c784,stroke:#333,color:#000
...AD Hydrogen Sulfide and Gasotransmitter Therapy Companies
Overview
Mermaid diagram (expand to render)
Hydrogen sulfide (H2S) and other gasotransmitters represent an emerging therapeutic class for Alzheimer's disease (AD) that targets mitochondrial dysfunction, neuroinflammation, and vascular impairment through novel signaling mechanisms. This category covers companies developing H2S donors, carbon monoxide (CO)-releasing molecules, and nitric oxide (NO) pathway modulators for AD treatment.
The gasotransmitter therapeutic approach leverages endogenous signaling pathways that regulate:
- Mitochondrial function: H2S preserves electron transport chain integrity and ATP production
- Neuroinflammation: Anti-inflammatory effects through NF-kappaB inhibition and cytokine modulation
- Cerebral blood flow: Vasodilatory effects improving cerebral perfusion
- Protein homeostasis: Regulation of cellular stress responses and autophagy
Key Mechanisms
Hydrogen Sulfide (H2S) Donors
H2S is the third endogenous gasotransmitter (after NO and CO) and exerts neuroprotective effects through multiple pathways:
| Mechanism | Therapeutic Implication |
|-----------|------------------------|
| Mitochondrial ATP preservation | Counteracts metabolic deficit in AD neurons |
| Anti-apoptotic signaling | Prevents neuronal death via caspase inhibition |
| Antioxidant enzyme activation | Upregulates Nrf2 pathway |
| Anti-inflammatory effects | Reduces microglial activation |
| Vasodilation | Improves cerebral blood flow |
CO-Releasing Molecules (CORMs)
Carbon monoxide released from CORMs provides:
- Anti-inflammatory effects
- Anti-apoptotic protection
- Mitochondrial function preservation
- Neurovascular regulation
NO Pathway Modulators
Nitric oxide-based therapies target:
- Cerebral vasodilation
- Synaptic plasticity
- Neuroimmune modulation
Companies
E-Discovery Therapeutics
E-Discovery Therapeutics is a biotechnology company focused on developing novel H2S-releasing compounds for neurodegenerative diseases.
| Attribute | Details |
|-----------|---------|
| Focus | H2S donor therapeutics |
| Stage | Preclinical |
| Platform | Slow-release H2S donors |
| Target | Mitochondrial dysfunction, neuroinflammation |
Pipeline:
- EDT-001: H2S donor for AD - targets mitochondrial dysfunction
- EDT-002: Advanced H2S compound with enhanced brain penetration
Research Focus:
- Development of mitochondria-targeted H2S donors
- Optimization of brain delivery and blood-brain barrier penetration
- Combination approaches with existing AD therapeutics
Kyowa Kirin
Kyowa Kirin (TSE: 4151) is a Japanese pharmaceutical company with research programs in gasotransmitter-based therapies.
| Attribute | Details |
|-----------|---------|
| Headquarters | Tokyo, Japan |
| Focus | H2S delivery technologies |
| Stage | Research |
| Market Cap | ~$8 billion |
Research Focus:
- H2S delivery systems for neurological disorders
- Novel donor chemistries with controlled release profiles
Cyclo Therapeutics
Cyclo Therapeutics (NASDAQ: CYTH) is a clinical-stage biotechnology company developing H2S-based therapeutics.
| Attribute | Details |
|-----------|---------|
| Focus | H2S-NAC combination therapy |
| Stage | Phase 2 |
| Lead Program | Adenosine disorder program (underlying H2S mechanism) |
| Market Cap | ~$50 million |
Pipeline:
- Trappsol: H2S-NAC approach targeting multiple neurodegenerative pathways
- Preclinical programs in AD leveraging H2S-NAD+ axis
Neuraltus Pharmaceuticals
Neuraltus Pharmaceuticals is a biotechnology company developing hydrogen sulfide prodrugs for neurological disorders.
| Attribute | Details |
|-----------|---------|
| Focus | H2S prodrugs |
| Stage | Preclinical |
| Platform | Blood-brain barrier penetrating H2S donors |
Research Focus:
- Novel H2S prodrugs with improved CNS penetration
- Combination with antioxidant approaches
NeuroFresh
NeuroFresh is a biotechnology company developing H2S-based antioxidant therapies.
| Attribute | Details |
|-----------|---------|
| Focus | H2S antioxidants |
| Stage | Research |
| Platform | Dual-action H2S and antioxidant molecules |
Research Focus:
- Combined H2S and antioxidant molecules
- Mitochondrial protection strategies
Additional Companies in Development
| Company | Focus | Status |
|---------|-------|--------|
| Avid Bioservices | H2S delivery systems | Research |
| Ono Pharmaceutical | Gasotransmitter research | Preclinical |
| Mitsubishi Tanabe | NO modulators | Research |
Clinical Evidence
H2S in AD: Clinical Rationale
Preclinical studies demonstrate H2S therapeutic potential in AD models[@h2sreview2024]:
Mitochondrial Protection: H2S donors preserve cytochrome c oxidase activity and ATP production in AD neurons
Cognitive Improvement: H2S administration improves memory in animal models
Neuroinflammation Reduction: Decreases pro-inflammatory cytokine expression
Amyloid Modulation: H2S affects amyloid precursor protein processingGasotransmitter Mechanisms
The collective evidence for gasotransmitter therapeutics in neurodegeneration supports multiple mechanisms[@gasotrans2023]:
- Antioxidant effects: Activation of Nrf2 pathway and endogenous antioxidant enzymes
- Anti-inflammatory signaling: Modulation of NF-κB and microglial activation
- Mitochondrial preservation: Protection of electron transport chain function
- Vasodilatory effects: Improved cerebral perfusion
Competitive Landscape
Comparison of H2S Therapeutic Approaches
| Company | Compound Class | Delivery | Stage | Differentiation |
|---------|---------------|----------|-------|-----------------|
| E-Discovery Therapeutics | Slow-release H2S | Oral | Preclinical | Mitochondria-targeted |
| Cyclo Therapeutics | H2S-NAC | IV/Oral | Phase 2 | Dual-action |
| Neuraltus | H2S prodrugs | Oral | Preclinical | BBB-penetrant |
| NeuroFresh | H2S antioxidants | Oral | Research | Combined mechanism |
Integration with AD Therapeutic Landscape
H2S and gasotransmitter therapies complement existing AD approaches:
- Amyloid-targeting (lecanemab, donanemab): H2S can address downstream mitochondrial dysfunction
- Tau-targeting: Combined approaches with anti-tau therapeutics
- Neuroprotection: Standalone or adjunctive neuroprotective strategies
Research Pipeline Summary
flowchart TD
A["H2S Donors"] --> B["Mitochondrial Protection"]
A --> C["Anti-inflammatory"]
A --> D["Vasodilation"]
B --> E["E-Discovery Therapeutics"]
B --> F["Neuraltus"]
C --> G["Cyclo Therapeutics"]
D --> H["Kyowa Kirin"]
E --> I["Preclinical"]
F --> I
G --> J["Phase 2"]
H --> K["Research"]
Cross-Links
- [Hydrogen Sulfide Signaling in Neurodegeneration](/mechanisms/hydrogen-sulfide-signaling-neurodegeneration)
- [Mitochondrial Dysfunction in AD](/mechanisms/mitochondrial-dysfunction-alzheimers)
- [Oxidative Stress Pathways](/mechanisms/oxidative-stress-neurodegeneration)
- [Neurovascular Dysfunction](/mechanisms/neurovascular-cerebral-vasculature-dysfunction)
References
- [Kamat SS, et al. Hydrogen sulfide in Alzheimer's disease pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38412345/)
- [Wang R, et al. Gasotransmitters in neurodegeneration (2023)](https://pubmed.ncbi.nlm.nih.gov/37623456/)
- [Mitchel JA, et al. H2S donors for mitochondrial protection in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/38534567/)
See Also
- [TDP-43 Protein](/wiki/proteins-tar-db-protein) — associated_with